Navigation Links
Experimental drug shows promise in advanced kidney cancer
Date:9/26/2007

Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumours ability to form new blood vessels that help it grow. Fourteen of the patients also had been given to no avail another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.

More than half the patients 51 percent experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant, said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.

The disease progressed in only 24 percent of patients, which we think is low in this kind of setting, Rini added. The study found the tumour remained stable in 37 percent of the patients.

Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large number of patients, Rini added.

The drugs maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.


'/>"/>

Contact: Emma Ross
rosswrite@mac.com
34-932-308-832
ECCO-the European CanCer Conference
Source:Eurekalert

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Experimental drug to fight flu
4. Experimental SARS Vaccine
5. Experimental vaccine for shingles is effective
6. Experimental Blood Test May Spot Heart Attack Risk, Study Says
7. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
8. TMC 114 and 125 experimental drugs to be tested on four HIV patients
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although ... the majority of skin cancer deaths. More than 10,000 people are expected to die of ... is 62, it is the one of the most commonly diagnosed cancers in young women. ...
(Date:4/29/2016)... ... , ... For those who skip meals occasionally (which is pretty much everyone), ... many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya Lawrence of ... show. Bonny and Lawrence noted that because proper nutrition, including water, provides energy during ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE Media ... on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower Lucy ... CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have dedicated ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend and ... at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event is ... for protein ingredients. , At the seminar, IDF™ will offer samples of its Savory ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions ... May 16th to 18th at the Broward County Convention Center. The event is ... collaborate on best practices in public facility management. Intellitec Solutions will highlight their ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
(Date:4/28/2016)... JERUSALEM , April 28, 2016 ... ), a clinical-stage pharmaceutical company focused on the development of ... participate in the upcoming PIONEERS 2016 conference, presented by ... 5, 2016 in New York . ... overview at the conference. Presentation Details:   ...
Breaking Medicine Technology: